Metal Metabolism, Inborn Errors: Clinical Trials

53 trials for Metal Metabolism, Inborn Errors, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

33 completed, 6 active not recruiting, 6 recruiting, 3 terminated. 53 Phase 2, 19 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 253Completed 33, Active not recruiting 6, Recruiting 6, Terminated 3, Enrolling by invitation 2, Withdrawn 2, Not yet recruiting 1
Phase 119Completed 10, Recruiting 6, Active not recruiting 2, Not yet recruiting 1
Phase 32Completed 2

Follow Metal Metabolism, Inborn Errors: new trials by email Literature Review of Metal Metabolism, Inborn Errors trials Research Report on Metal Metabolism, Inborn Errors

Trials (filtered) newest first · largest first

All 53 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)
PM577a - Wilson Disease, Wilson's Disease
Phase 1 / Phase 2RecruitingPrime Medicine, Inc.422026-09-012026-10-01
NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease
Droxidopa Oral Product, Placebo Control - Menkes Disease
Phase 1 / Phase 2RecruitingStephen G. Kaler62026-08-102026-10-05
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
Setmelanotide - Pseudohypoparathyroidism Type 1a, Obesity
Phase 2Enrolling by invitationMassachusetts General Hospital12026-07-212026-07-23
Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease
LY-M003 Injection - Wilson's Disease
Phase 1 / Phase 2Not yet recruitingLingyi Biotech Co., Ltd.182026-06-152026-07-02
A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis
BBI-001, Placebo - Hereditary Hemochromatosis
Phase 1 / Phase 2RecruitingBond Biosciences342026-05-042026-05-13
Evaluation of the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)
GC310 - Wilson Disease
Phase 1 / Phase 2RecruitingGeneCradle Inc152026-02-202026-11-17
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
Vamifeport, Placebo - Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis
Phase 2Active not recruitingCSL Behring842026-01-222026-10-21
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
ALE1, Placebo - Hypophosphatasia (HPP)
Phase 1 / Phase 2RecruitingAlesta Therapeutics1202025-09-302026-08-03
Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride
New TETA 4HCl Formulation, Standard of Care - Wilson's Disease
Phase 2CompletedOrphalan102025-07-152026-04-06
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
KK8123 - X-linked Hypophosphatemia
Phase 1 / Phase 2RecruitingKyowa Kirin Co., Ltd.392024-10-092026-11-06
Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia
Ilofotase Alfa, 0.8 mg/kg, Ilofotase Alfa, 3.2 mg/kg - Hypophosphatasia
Phase 1 / Phase 2CompletedAM-Pharma122023-05-152025-02-27
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
UX701, Standard of Care (SOC) - Wilson Disease
Phase 1 / Phase 2Active not recruitingUltragenyx Pharmaceutical Inc822021-09-272026-09-25
A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease
VTX-801 - Wilson's Disease
Phase 1 / Phase 2Active not recruitingVivet Therapeutics SAS42021-09-032026-01-30
NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome
Droxidopa, Placebo - Menkes Disease, Occipital Horn Syndrome
Phase 1 / Phase 2CompletedStephen G. Kaler, MD32021-07-122026-04-13
Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
Bis-Choline Tetrathiomolybdate - Wilson Disease
Phase 2CompletedAlexion Pharmaceuticals, Inc.312020-12-022024-10-18
Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
ALXN1840 - Wilson Disease
Phase 2CompletedAlexion Pharmaceuticals, Inc.92020-09-072024-06-24
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old
Theophylline, Placebo - Pseudohypoparathyroidism, Albright Hereditary Osteodystrophy
Phase 2Active not recruitingVanderbilt University Medical Center342020-07-132026-04-29
Theophylline for Treatment of Pseudohypoparathyroidism
Theophylline ER - Pseudohypoparathyroidism, Pseudohypoparathyroidism Type 1a
Phase 2Enrolling by invitationJaclyn Tamaroff342020-05-222026-09-02
PTG-300 in Subjects With Hereditary Hemochromatosis
PTG-300 - Hereditary Hemochromatosis
Phase 2CompletedProtagonist Therapeutics, Inc.162020-03-192025-08-20
Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
Burosumab - X-linked Hypophosphatemia (XLH)
Phase 1 / Phase 2CompletedKyowa Kirin Pharmaceutical Development Ltd162020-02-262024-11-07

Showing 20 of 53. Sign in to see all of them.

Narrower conditions

Hemochromatosis (14)  ·  Hypophosphatasia (12)  ·  Hepatolenticular Degeneration (9)  ·  Familial Hypophosphatemic Rickets (8)  ·  Iron Overload (8)  ·  Bone Diseases (7)  ·  Osteomalacia (7)  ·  Rickets (7)  ·  Pseudohypoparathyroidism (6)  ·  Menkes Kinky Hair Syndrome (3)  ·  Thalassemia (3)  ·  Autonomic Nervous System Diseases (2)  ·  Myelodysplastic Syndromes (2)  ·  Anemia (1)  ·  Anemia, Diamond-Blackfan (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (53)  ·  Genetic Diseases, Inborn (53)  ·  Metabolism, Inborn Errors (53)  ·  Nutritional and Metabolic Diseases (53)  ·  Metabolic Diseases (52)  ·  Musculoskeletal Diseases (22)  ·  Bone Diseases, Metabolic (21)  ·  Calcium Metabolism Disorders (21)  ·  Nutrition Disorders (16)  ·  Avitaminosis (15)  ·  Deficiency Diseases (15)  ·  Malnutrition (15)  ·  Vitamin D Deficiency (15)  ·  Bone Diseases (14)

Interventions

asfotase alfa (9)  ·  burosumab (6)  ·  Deferasirox (4)  ·  Deferoxamine (3)  ·  Phlebotomy (3)  ·  Theophylline (3)  ·  Droxidopa (2)  ·  Standard of Care (2)  ·  Bumetanide (1)  ·  Deferiprone (1)  ·  Growth Hormone (1)  ·  Interleukin 1 Receptor Antagonist Protein (1)  ·  Long Interspersed Nucleotide Elements (1)  ·  Saline Solution (1)  ·  copper histidine (1)

Sponsors

Alexion Pharmaceuticals, Inc. (11)  ·  Kyowa Kirin Co., Ltd. (3)  ·  Kyowa Kirin, Inc. (3)  ·  Novartis Pharmaceuticals (3)  ·  Vanderbilt University Medical Center (3)  ·  Rennes University Hospital (2)  ·  Ultragenyx Pharmaceutical Inc (2)  ·  AM-Pharma (1)  ·  Alesta Therapeutics (1)  ·  Bicetre Hospital (1)  ·  Bond Biosciences (1)  ·  CSL Behring (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  GeneCradle Inc (1)  ·  Haukeland University Hospital (1)

Countries

United States (32)  ·  United Kingdom (16)  ·  Canada (13)  ·  France (10)  ·  Germany (10)  ·  Spain (7)  ·  Italy (6)  ·  Australia (5)  ·  New Zealand (5)  ·  Austria (3)  ·  China (3)  ·  Denmark (3)  ·  Russia (3)  ·  Switzerland (3)  ·  United Arab Emirates (3)

Top investigators

Jaclyn Tamaroff, MD (3)  ·  Amy Zhang, PhD (2)  ·  Eugene S. Swenson, MD, PhD (2)  ·  Anna Davidsson (1)  ·  Ashley H Shoemaker, MD, MSCI (1)  ·  Chaohui Yu, PhD (1)  ·  Curtis Scribner, MD (1)  ·  Doreen Fialho, MD, PhD (1)  ·  Eugene Swenson, MD, PhD (1)  ·  Francesco Equitani, M.D. (1)  ·  Keiichi Ozono (1)

Results publications

PMID 26529632, PMID 32417537, PMID 32762706, PMID 25919461, PMID 27699270, PMID 32721016, PMID 39151033, PMID 15923132, PMID 16278898, PMID 17482283, PMID 17959863, PMID 18256395, PMID 18752978, PMID 19194885, PMID 20497190, PMID 20652413, PMID 22134099, PMID 22397652, PMID 2265118, PMID 24385534, PMID 24916507, PMID 25281031, PMID 25345697, PMID 26073451, PMID 28436937, PMID 28822957, PMID 28988934, PMID 29791829, PMID 30558909, PMID 30638856, PMID 30811537, PMID 30969260, PMID 32987199, PMID 33822385, PMID 34636899, PMID 36072994, PMID 37863080, PMID 41378916, PMID 42016919, PMID 42044650, PMID 7842019, PMID 8295415, PMID 8419622, PMID 8526465, PMID 8812725, PMID 9633879

NIH funding

2025 (2), 2014 (1), 2016 (1), 2019 (1)